Dermatologists have not traditionally played a systematic role in recommending and administering immunizations.
Xellia announced that the Food and Drug Administration (FDA) has approved its Premixed Vancomycin Injection in a Ready-to-Use bag.
For patients colonized with methicillin-resistant Staphylococcus aureus (MRSA), postdischarge MRSA decolonization is associated with a reduced risk for infection.
The NDA included data from the Phase 3 REVIVE-1 and REVIVE-2 trials.
Over the study period, significant increases in the number of screening tests, as well as the ratio between the tests and hospital admissions, was observed.
Although there has been progress in the development of new antibacterial drugs, most of the recently approved agents have been modifications of existing chemical classes of antibiotics.
Nuzyra, an aminomethylcycline (related to tetracycline antibiotics), is designed to overcome tetracycline resistance and has broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria, and other drug-resistant strains.
The 2007 and 2008 shingles and varicella vaccination recommendations may have contributed to the declining herpes zoster hospitalization rates in some groups.
Omadacycline is noninferior to moxifloxacin for community-acquired bacterial pneumonia and noninferior to linezolid for acute bacterial skin infections.
During the first eight months of recombinant zoster vaccine (RZV) use, there were reports of 4,381 adverse events, 3 percent of which were serious.